WHO review in Lancet Microbe lists SynAct’s resomelagon candidate therapy
A WHO review published in Lancet Microbe names SynAct Pharma’s resomelagon as one of six dengue therapeutic candidates, citing evidence for further clinical development.
A WHO review in Lancet Microbe names SynAct Pharma’s resomelagon as one of six dengue therapeutic candidates with evidence supporting further clinical development, and says it is the only host-directed therapy on the list.